Stimulating action of estradiol dipropionate on induction of sarcomas of the uterus by 1,2-dimethylhydrazine in mice

1980 ◽  
Vol 90 (5) ◽  
pp. 1586-1588
Author(s):  
V. S. Turusov ◽  
A. B. Linnik ◽  
O. V. Morozova
2019 ◽  
Vol 90 (12) ◽  
pp. 1523-1529 ◽  
Author(s):  
Yuri Hirayama ◽  
Koji Yoshioka ◽  
Michiko Noguchi ◽  
Koji Misumi

1985 ◽  
Vol 6 (1) ◽  
pp. 109-111 ◽  
Author(s):  
R.J. Salmon ◽  
J.P. Buisson ◽  
L. Aussepe ◽  
R. Royer

1980 ◽  
Vol 90 (6) ◽  
pp. 1720-1722
Author(s):  
L. M. Shabad ◽  
L. V. Olyshevskaya

2013 ◽  
Vol 27 (18) ◽  
pp. 1986-1998 ◽  
Author(s):  
C. Lu ◽  
S. Venneti ◽  
A. Akalin ◽  
F. Fang ◽  
P. S. Ward ◽  
...  

PEDIATRICS ◽  
1960 ◽  
Vol 26 (3) ◽  
pp. 347-350
Author(s):  
Irving Schulman

Two Articles in this issue of Pediatrics report on the use of an iron-dextran complex (Imferon), a preparation which, on April 25, 1960, was withdrawn from the American market. This action was taken by the distributor, Lakeside Laboratories, upon recommendation of the Food and Drug Administration and followed publication of experiments which demonstrated the induction of sarcomas in mice and rats at the sites of repeated injections of the drug. In view of the extensive clinical use of Imferon in recent years it seems appropriate to review critically the evidence for the possible carcinogenicity of the preparation and the justification for its removal from the market.


Sign in / Sign up

Export Citation Format

Share Document